$135.00
-1.64-1.2%
Last update: Nov 11, 12:02 PM
Kymera Therapeutics Inc
KYMRNASDAQ
The average analyst price target for Kymera Therapeutics is $118.91, 11.9% below the current price. Of 25 analysts, 22 rate it Buy and 3 Hold. Targets range from $44 to $170. The latest change came on Nov 2, 2026, when Barclays raised its price target on Kymera Therapeutics from $139 to $170 and kept an Overweight rating.
Price Target Range — 11 Quarters
Analyst Consensus — 25 Analysts
Rating Trend — Last 9 Months
